iiinova — where your digital self keeps evolving

Reposted by MattBloodMD

Saskia Middeldorp @middeldorps.bsky.social · 10/12/2024

Extended-dose DOAC vs full-dose DOAC #Renove trial #ASH24 Late breaking abstract. Officially, reduced dose was not non-inferior, but recurrent #VTE rates were low and there is a substantial reduction in major and non-major bleeding. Congratulations to the French colleagues of #Innovte!

0162

Reposted by MattBloodMD

MattBloodMD @doctorblood.bsky.social · 29/11/2024

We humbly thank the reviewers for their suggestions. We would like to resubmit this improved manuscript for your consideration. #AcademicSky #MedSky

912621

MattBloodMD @doctorblood.bsky.social · 29/11/2024

We humbly thank the reviewers for their suggestions. We would like to resubmit this improved manuscript for your consideration. #AcademicSky #MedSky

912621

Reposted by MattBloodMD

Nicolas Gendron @gendronn.bsky.social · 27/11/2024

🎉Congratulations Francis and the 🇫🇷 INNOVTE team for the RENOVE study that will be presented at ASH 2024 @ash-hematology.bsky.social as a Late-Breaking Abstract ! 💊Reduced- Vs Full dose of DOAC for long terme anticoagulation after VTE ⤵️ ash.confex.com/ash/2024/web...

ash.confex.com

Paper: Extended Treatment of Venous Thromboembolism with Reduced- Vs Full-Dose Direct Oral Anticoagulants in Patients at High Risk of Recurrence

093